AR088564A1 - PROCESO PARA LA PREPARACION DE AGONISTAS Y COMPUESTOS INTERMEDIOS DE b3 - Google Patents

PROCESO PARA LA PREPARACION DE AGONISTAS Y COMPUESTOS INTERMEDIOS DE b3

Info

Publication number
AR088564A1
AR088564A1 ARP120104036A ARP120104036A AR088564A1 AR 088564 A1 AR088564 A1 AR 088564A1 AR P120104036 A ARP120104036 A AR P120104036A AR P120104036 A ARP120104036 A AR P120104036A AR 088564 A1 AR088564 A1 AR 088564A1
Authority
AR
Argentina
Prior art keywords
compound
formula
produce
catalyst
reduction
Prior art date
Application number
ARP120104036A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR088564A1 publication Critical patent/AR088564A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Reivindicación 1: Un proceso para la preparación del compuesto de fórmula (1), que comprende: (a) reacción del compuesto de fórmula (2), con un reactivo protector de acetonida seleccionado entre el grupo que consiste en 2,2-dimetoxipropano, 2,2-dietoxipropano, 2-metoxipropeno y acetona, para producir el compuesto de fórmula (3); (b) reducción del compuesto de fórmula (3) con un agente reductor a una temperatura de 0ºC a 40ºC para producir el compuesto de fórmula (4); (c) oxidación del compuesto de fórmula (4) con un agente oxidante en presencia de un disolvente y de un catalizador para producir el compuesto de fórmula (5); (d) reacción del compuesto de fórmula (5) con un compuesto de fosfato de fórmula (6) para producir el compuesto de fórmula (7); (e) reducción del compuesto de fórmula (7) en presencia de un catalizador para producir el compuesto (8); (f) reacción del compuesto de fórmula (8) con un ácido para producir el compuesto de fórmula (9); (g) reducción del compuesto de fórmula (9) en presencia de un catalizador para producir el compuesto de fórmula (1); en el que cada uno de P¹ y P² se selecciona independientemente entre el grupo que consiste en Ac, Bn, Boc, Bz, Cbz, DMPM, FMOC, Ns, Moz, y Ts; y R¹ se selecciona entre el grupo que consiste en alquilo C₁₋₆, bencilo y fenilo.
ARP120104036A 2011-10-27 2012-10-26 PROCESO PARA LA PREPARACION DE AGONISTAS Y COMPUESTOS INTERMEDIOS DE b3 AR088564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161552200P 2011-10-27 2011-10-27

Publications (1)

Publication Number Publication Date
AR088564A1 true AR088564A1 (es) 2014-06-18

Family

ID=48168357

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104036A AR088564A1 (es) 2011-10-27 2012-10-26 PROCESO PARA LA PREPARACION DE AGONISTAS Y COMPUESTOS INTERMEDIOS DE b3

Country Status (7)

Country Link
US (4) US9809536B2 (es)
EP (1) EP2771006B1 (es)
JP (1) JP6088535B2 (es)
AR (1) AR088564A1 (es)
ES (1) ES2584427T3 (es)
TW (1) TW201323406A (es)
WO (1) WO2013062878A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
EP2770996B1 (en) 2011-10-27 2016-09-28 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． β−３作動薬および中間体の製造方法
AU2018282104A1 (en) 2017-06-06 2019-12-12 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
AU2018282105A1 (en) 2017-06-06 2019-12-12 Urovant Sciences Gmbh Dosing of vibegron for treatment of overactive bladder
WO2019224788A1 (en) 2018-05-23 2019-11-28 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
EP3890743A1 (en) 2018-12-05 2021-10-13 Urovant Sciences GmbH Vibegron for the treatment of overactive bladder symptoms
JP2022524576A (ja) 2019-03-18 2022-05-09 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を処置するためのビベグロンの使用
US20220372542A1 (en) * 2019-10-02 2022-11-24 Abbott Diabetes Care Inc. Detection of analytes by protein switches
CN112708644B (zh) * 2019-10-25 2024-05-28 弈柯莱生物科技(集团)股份有限公司 氟苯尼考中间体的制备方法
CN112176007B (zh) * 2020-10-12 2022-07-22 上海医药工业研究院 一种氨基醇手性中间体的制备方法
TW202239412A (zh) 2020-12-22 2022-10-16 瑞士商優洛凡特科學公司 使用維貝格隆（ｖｉｂｅｇｒｏｎ）並監測地高辛（ｄｉｇｏｘｉｎ）以治療膀胱過動症的方法
TW202245781A (zh) 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法
GB202113588D0 (en) * 2021-09-23 2021-11-10 Atrogi Ab New compounds and methods
CN113816917B (zh) * 2021-11-19 2022-02-18 奥锐特药业(天津)有限公司 一种维贝格龙中间体的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
WO2009036404A2 (en) * 2007-09-13 2009-03-19 Codexis, Inc. Ketoreductase polypeptides for the reduction of acetophenones
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2329014B1 (en) 2008-08-29 2014-10-22 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
NZ599233A (en) 2009-10-07 2013-04-26 Merck Sharp & Dohme Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
EP2770996B1 (en) 2011-10-27 2016-09-28 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
CN104053771B (zh) 2011-11-18 2016-11-09 科德克希思公司 用于制备羟基取代的氨基甲酸酯的生物催化剂
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． β−３作動薬および中間体の製造方法

Also Published As

Publication number Publication date
EP2771006B1 (en) 2016-05-25
WO2013062878A1 (en) 2013-05-02
US20180029981A1 (en) 2018-02-01
EP2771006A1 (en) 2014-09-03
US20140242645A1 (en) 2014-08-28
US11767292B2 (en) 2023-09-26
US9809536B2 (en) 2017-11-07
US10577316B2 (en) 2020-03-03
JP6088535B2 (ja) 2017-03-08
EP2771006A4 (en) 2015-04-15
JP2015501319A (ja) 2015-01-15
US20200290962A1 (en) 2020-09-17
ES2584427T3 (es) 2016-09-27
US11124478B2 (en) 2021-09-21
TW201323406A (zh) 2013-06-16
US20220073459A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
AR088564A1 (es) PROCESO PARA LA PREPARACION DE AGONISTAS Y COMPUESTOS INTERMEDIOS DE b3
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
EA201791873A1 (ru) Полиморф ингибиторов syk
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
BR112014030365A2 (pt) síntese de composto antiviral
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
BR112015001839A2 (pt) ibrutinibe deuterado
TR201906413T4 (tr) Bir makrosiklik hcv ns3 inhibe edici tripeptidin sentezi.
BR112014029551A2 (pt) compostos de ácido dimetil-benzoico
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
CU24366B1 (es) Compuestos que poseen un anillo que contiene nitrógeno salicílico unido a un grupo heteroarilo bicíclico útiles como inhibidores rorc2
ES2721659T3 (es) Aparato para generar 1-metilciclopropeno
MX358429B (es) Nuevos derivados de isocromano e isotiocromano agonistas del adrenoreceptor alfa2a, especialmente agonistas del adrenoreceptor alfa2a para usarse como sedantes o analgesicos.
PE20131098A1 (es) Proedimiento de preparacion de la sal de l-arginina de perindoprilo
EA201590770A1 (ru) Ингибиторы вируса гепатита с
BR112013010850A2 (pt) composto de etinilfenilamidina ou sal do mesmo, método para produzir o mesmo e fungicida para uso agrícola e em horticultura
PE20140917A1 (es) Sintesis de derivados de 2-carboxamida-cicloamino-urea
AR101136A1 (es) Proceso para la preparación de ácidos 3-hidroxipicolínicos
AR088358A1 (es) Proceso de obtencion de acidos isoxazolil-metoxi-nicotinicos
AR081804A1 (es) Composicion de control de fitoenfermedades y metodo para controlar fitoenfermedades
AR087345A1 (es) Metodos para la preparacion de compuestos de tiofeno
EA201401277A1 (ru) Соединения метантиона, обладающие противовирусной активностью
BR112016007618A2 (pt) métodos de síntese química de compostos de diaminofenotiazínio incluindo cloreto de metiltionínio (mtc)

Legal Events

Date Code Title Description
FG Grant, registration